Description

Simple

Clinical

Overview

MAXY-G34 is a pegylated variant of human granulocyte-colony stimulating factor (G-CSF). This variant contains multiple non-naturally occurring lysines that have been introduced into alpha helixes of wild type human G-CSF as PEGylation sites, and from which multiple undesired, naturally occurring lysines have been removed as compared to wild type human G-CSF to avoid PEGylation of such sites. Specifically, the amino acid sequence of MAXY-G34 differs from that of human wild type G-CSF at residues 16, 34, 40, 105 and 159. This was accomplished by removing the three lysine residues at positions 16, 34 and 40, and replacing them with arginine, and substituting two new lysine residues at positions 105 and 159. MAXY-G34 is pegylated with 5 kd mPEG SPA (succinimidyl propionate) groups at 3 amino acid residues, including PEG groups attached at the amino terminal end of the protein and at two internal lysine residues, while Neulasta has a single 20 Kd PEG group attached at the N terminal end of the wild type G-CSF protein. It is being developed by Maxygen, Inc. for the treatment of chemotherapy-induced neutropenia.

Pharmacology

Indication

Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.

Pharmacodynamic

Maxy-G34 is a PEGylated proprietary G-CSF variant designed to be administered as a single subcutaneous injection once per chemotherapy cycle. Maxygen has made changes in the G-CSF gene sequence that code for novel PEGylation sites in the resulting protein. In contrast to the currently marketed PEGyl... Read more

Mechanism of action

Neutropenia is a severe decrease in neutrophil cell counts in the blood. Neutropenia is a common side effect of chemotherapeutic treatments for many forms of cancer, including breast cancer, lung cancer, lymphomas and leukemias. Neutropenic patients contract bacterial infections more easily and ofte... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Maxy-G34
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Cyclophosphamide
The risk or severity of pulmonary toxicity can be increased when Maxy-G34 is combined with Cyclophosphamide.
Vinblastine
The risk or severity of peripheral neuropathy can be increased when Maxy-G34 is combined with Vinblastine.
Vincamine
The risk or severity of peripheral neuropathy can be increased when Maxy-G34 is combined with Vincamine.
Vincristine
The risk or severity of peripheral neuropathy can be increased when Maxy-G34 is combined with Vincristine.
Vindesine
The risk or severity of peripheral neuropathy can be increased when Maxy-G34 is combined with Vindesine.
Vinflunine
The risk or severity of peripheral neuropathy can be increased when Maxy-G34 is combined with Vinflunine.
Vinorelbine
The risk or severity of peripheral neuropathy can be increased when Maxy-G34 is combined with Vinorelbine.
Vintafolide
The risk or severity of peripheral neuropathy can be increased when Maxy-G34 is combined with Vintafolide.